An analysis of brains at various stages of Alzheimer's found that neurons called inhibitory neurons are the first to be affected by the disease.

A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to ...

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

The findings suggest that Alzheimer’s treatments are most likely to help early in the disease, and that one strategy might be ...

If you've been looking for a sign to work on your sleep hygiene, this is it. A new study suggests that a particular wave of ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

A compassionate, multidisciplinary approach can help manage one of the most complex challenges nursing homes and other long-term care providers face.